QR Code

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2025-07-01
Rangatū:BMC Cancer
Ngā marau:
atezolizumab
bevacizumab
hepatocellular carcinoma
real world
immune checkpoint inhibitors
Urunga tuihono:https://doi.org/10.1186/s12885-025-14400-9
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite